Atossa Therapeutics Inc (NASDAQ:ATOS) has found its new chief financial officer in veteran life sciences executive and longtime board member Greg Weaver.
Weaver brings more than 30 years of life science, financial and operations experience to Atossa, most recently serving as CFO BioIntelliSense, a privately held medtech company.
He also held the same role at Atai Life Sciences, where he helped lead an IPO, managed the acquisition of multiple mental health therapeutics assets and raised more than $500 million to advance multiple clinical and discovery programs.
Before that, he led a reverse merger as the CFO of Eloxx Pharmaceuticals Inc (NASDAQ:ELOX).
“We are excited to welcome Greg as our CFO and look forward to drawing from his broad experience leading biotech companies and partnering innovative products and programs within the biotechnology industry,” Atossa CEO Steven Quay said in a statement.
“Greg is a trusted colleague that I and other members of the Atossa board have had the pleasure of working alongside in previous board and management roles. Greg has served on the board of Atossa since the beginning, and I am confident that his expertise in life sciences corporate strategy, financing and business development will be a vital addition to Atossa as our programs progress in later stages of clinical development.”
Weaver replaces outgoing CFO Kyle Guse.
“I’m excited to join Atossa’s executive team as we continue to advance the company’s Phase 2 clinical trials in breast cancer and mammographic breast density,” Weaver said. “Atossa is at a critical stage in its development with key clinical data readouts expected over the next year and with a strong multi-year cash position. I look forward to working on behalf of our shareholders, partners and patients to fully capitalize on the value of (Z)-endoxifen and to fundamentally change the breast cancer paradigm.”
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel